Denmark · Delayed Price · Currency is DKK Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of DKK 91.03 billion. The enterprise value is 114.20 billion.
| Market Cap | 91.03B |
| Enterprise Value | 114.20B |
Important Dates
The last earnings date was Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | May 18, 2026 |
Share Statistics
Coloplast has 225.17 million shares outstanding.
| Current Share Class | 207.17M |
| Shares Outstanding | 225.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 5.33% |
| Owned by Institutions (%) | 22.79% |
| Float | 143.38M |
Valuation Ratios
The trailing PE ratio is 43.28 and the forward PE ratio is 15.92. Coloplast's PEG ratio is 1.78.
| PE Ratio | 43.28 |
| Forward PE | 15.92 |
| PS Ratio | 3.25 |
| PB Ratio | 7.09 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.00 |
| P/OCF Ratio | 11.99 |
| PEG Ratio | 1.78 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.67, with an EV/FCF ratio of 18.81.
| EV / Earnings | 54.22 |
| EV / Sales | 4.07 |
| EV / EBITDA | 9.67 |
| EV / EBIT | 15.05 |
| EV / FCF | 18.81 |
Financial Position
The company has a current ratio of 1.75, with a Debt / Equity ratio of 1.89.
| Current Ratio | 1.75 |
| Quick Ratio | 1.01 |
| Debt / Equity | 1.89 |
| Debt / EBITDA | 2.05 |
| Debt / FCF | 3.99 |
| Interest Coverage | 11.64 |
Financial Efficiency
Return on equity (ROE) is 14.14% and return on invested capital (ROIC) is 12.58%.
| Return on Equity (ROE) | 14.14% |
| Return on Assets (ROA) | 9.90% |
| Return on Invested Capital (ROIC) | 12.58% |
| Return on Capital Employed (ROCE) | 18.66% |
| Weighted Average Cost of Capital (WACC) | 5.89% |
| Revenue Per Employee | 1.64M |
| Profits Per Employee | 123,280 |
| Employee Count | 17,083 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 2.36 |
Taxes
In the past 12 months, Coloplast has paid 1.34 billion in taxes.
| Income Tax | 1.34B |
| Effective Tax Rate | 38.85% |
Stock Price Statistics
The stock price has decreased by -37.26% in the last 52 weeks. The beta is 0.50, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -37.26% |
| 50-Day Moving Average | 428.22 |
| 200-Day Moving Average | 535.15 |
| Relative Strength Index (RSI) | 42.96 |
| Average Volume (20 Days) | 370,086 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of DKK 28.05 billion and earned 2.11 billion in profits. Earnings per share was 9.34.
| Revenue | 28.05B |
| Gross Profit | 18.92B |
| Operating Income | 7.59B |
| Pretax Income | 3.44B |
| Net Income | 2.11B |
| EBITDA | 11.52B |
| EBIT | 7.59B |
| Earnings Per Share (EPS) | 9.34 |
Balance Sheet
The company has 1.07 billion in cash and 24.23 billion in debt, with a net cash position of -23.16 billion or -102.86 per share.
| Cash & Cash Equivalents | 1.07B |
| Total Debt | 24.23B |
| Net Cash | -23.16B |
| Net Cash Per Share | -102.86 |
| Equity (Book Value) | 12.84B |
| Book Value Per Share | 57.04 |
| Working Capital | 4.47B |
Cash Flow
In the last 12 months, operating cash flow was 7.60 billion and capital expenditures -1.52 billion, giving a free cash flow of 6.07 billion.
| Operating Cash Flow | 7.60B |
| Capital Expenditures | -1.52B |
| Depreciation & Amortization | 3.93B |
| Net Borrowing | -220.00M |
| Free Cash Flow | 6.07B |
| FCF Per Share | 26.96 |
Margins
Gross margin is 67.46%, with operating and profit margins of 27.05% and 7.51%.
| Gross Margin | 67.46% |
| Operating Margin | 27.05% |
| Pretax Margin | 12.28% |
| Profit Margin | 7.51% |
| EBITDA Margin | 41.07% |
| EBIT Margin | 27.05% |
| FCF Margin | 21.65% |
Dividends & Yields
This stock pays an annual dividend of 23.00, which amounts to a dividend yield of 5.69%.
| Dividend Per Share | 23.00 |
| Dividend Yield | 5.69% |
| Dividend Growth (YoY) | 4.55% |
| Years of Dividend Growth | 17 |
| Payout Ratio | 246.15% |
| Buyback Yield | n/a |
| Shareholder Yield | 5.76% |
| Earnings Yield | 2.31% |
| FCF Yield | 6.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 19, 2012. It was a forward split with a ratio of 5.
| Last Split Date | Dec 19, 2012 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Coloplast has an Altman Z-Score of 4.01 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.01 |
| Piotroski F-Score | 6 |